Case Report: Recovery of One ICU-Acquired COVID-19 Patient Via Ozonated Autohemotherapy
The Innovation, DOI: 10.1016/j.xinn.2020.100060
15 Pages Posted: 8 Apr 2020 Last revised: 10 Nov 2020
Date Written: March 26, 2020
The rapid spread of COVID-19 results in a pandemic throughout the world, however, there are currently no specific treatments available. We report the first case of ozonated autohemotherapy for a critically ill patient with COVID-19. The patient was diagnosed with severe acute respiratory distress syndrome (ARDS) and life-threatening refractory hypoxemia within 72 hours of the intensive-care unit (ICU) admission. To improve the oxygen delivery, the ozonated autohemotherapy was performed with 40 µg/ml of ozone in 100 ml of blood for 5 days on this patient, who then recovered from ARDS uneventfully and discharged from hospital after viral clearance. This case suggests ozonated autohemotherapy might be an alternative non-invasive medical treatment for critically ill COVID-19 patients.
Note: Funding: Supported by the National Natural Science Foundation and the Tianjin University COVID-19 Contingency fund.
Conflict of Interest: None declared.
Ethical Approval: This clinical protocol was approved as a complementary therapy by the institutional review board of Tianjin University Haihe Hospital on February 16, 2020, while the patient would continue to be treated with allopathic medicine. The patient was an adult recruited from COVID-19 specified ICU at Haihe hospital, and signed an informed consent about medical ozonated autohemotherapy on February 20, 2020.
Suggested Citation: Suggested Citation